EP Edge Journal Watch: Cardiac Electrophysiology Research

Niraj Sharma MD FACC FHRS: Cardiac Electrophysiology & Cardiology
  • 0,0 (0)
  • Biowissenschaften

Welcome to EP Edge Journal Watch, where cardiac electrophysiology meets evidence, precision, and perspective. Hosted by Dr. Niraj Sharma, this weekly podcast distills high-impact cardiovascular and Cardiac Electrophysiology and arrhythmia research into clear, clinically meaningful insights. Each episode goes beyond headlines and abstracts to uncover what new studies actually mean for patient care, decision-making, and the future of electrophysiology. What EP Edge Journal Watch stands for: Evidence-based practice Precision electrophysiology, arrhythmias analysis A forward-thinking, edge-driven approach to how we interpret and apply data in real-world clinical settings. Whether you’re an electrophysiologist, cardiologist, researcher, trainee, or allied health professional, EP Edge Journal Watch brings you the signal not the noise. Expect sharp summaries, thoughtful commentary, and practical takeaways designed for the busy clinician who wants to stay ahead of the curve

  1. vor 4 Tagen

    EP Edge® × HRS: Rethinking the Defaults: AFib Ablation vs Antiarrhythmics, Flecainide Beyond CAST, and Physiologic Pacing

    In this EP Edge and Heart Rhythm Society collaborative podcast, Dr. Niraj Sharma and Dr. Mike Lloyd examine new evidence challenging several long-standing assumptions in cardiac electrophysiology: when to choose catheter ablation over antiarrhythmic drug therapy for atrial fibrillation, whether left bundle branch area pacing should replace conventional right ventricular pacing in patients who require substantial ventricular pacing, and how broadly the lessons of CAST should continue to restrict flecainide and other Class Ic antiarrhythmic drugs. The atrial fibrillation discussion brings together two complementary 2026 Heart Rhythm meta-analyses. Demy L. Idema and colleagues evaluated antiarrhythmic drugs versus catheter ablation for rhythm control across randomized controlled trials, focusing on AF recurrence, hospitalization, mortality, and treatment-related complications. Marwan Shawki and colleagues examined the safety of catheter ablation versus antiarrhythmic drugs across 24 randomized trials involving 6,665 participants. Together, the studies raise an important contemporary question: as ablation becomes more effective and procedural safety improves, does antiarrhythmic drug therapy still deserve an automatic position ahead of ablation in the AF treatment pathway? The discussion then turns to physiologic pacing and the PACE-HF trial by Jenish P. Shroff and colleagues, published in the European Heart Journal. In this prospective randomized trial, left bundle branch area pacing was compared with conventional right ventricular pacing in patients with preserved or mildly reduced left ventricular ejection fraction who were expected to require substantial ventricular pacing. The trial provides randomized evidence on ventricular function, pacing burden, heart failure hospitalization, and the potential consequences of chronic nonphysiologic right ventricular activation. Finally, the podcast revisits flecainide more than three decades after the Cardiac Arrhythmia Suppression Trial (CAST). The discussion incorporates the systematic review by Li and colleagues in Heart Rhythm examining how CAST reshaped flecainide research and clinical use, together with the nationwide cohort study by T.-C. Huang and colleagues in Heart Rhythm evaluating Class Ic antiarrhythmic therapy after PCI in patients with new-onset atrial fibrillation. The central question is not whether CAST was correct in the post-myocardial-infarction population it studied, but whether its findings have been extrapolated too broadly to contemporary patients with stable or revascularized coronary disease, preserved ventricular function, and atrial rather than ventricular arrhythmias. Across atrial fibrillation ablation, conduction-system pacing, and Class Ic antiarrhythmic therapy, the episode asks a common question: when new evidence challenges an established electrophysiology default, when is the evidence strong enough to change everyday practice? Studies Discussed Idema DL, et al. Antiarrhythmic drugs vs catheter ablation as rhythm control for atrial fibrillation: A systematic review and meta-analysis of randomized controlled trials. Heart Rhythm. 2026;23:1465-1475. Shawki M, et al. Safety of catheter ablation compared with antiarrhythmic drugs for atrial fibrillation: A systematic review and meta-analysis of randomized trials. Heart Rhythm. 2026;23:1453-1464. Shroff JP, et al. Left bundle branch area pacing vs right ventricular pacing in preserved or mildly reduced ejection fraction: the PACE-HF trial. European Heart Journal. 2026;47:3298-3300. Li et al. Flecainide use before and after the Cardiac Arrhythmia Suppression Trial: A systematic review. Heart Rhythm. 2026. Huang TC, et al. Class Ic antiarrhythmic therapy after PCI in new-onset atrial fibrillation: Safety and clinical outcomes from a nationwide cohort. Heart Rhythm. 2026;23:e1372-e1382.

    EP Edge® × HRS: Rethinking the Defaults: AFib Ablation vs Antiarrhythmics, Flecainide Beyond CAST, and Physiologic Pacing

  2. 24. Aug.

    EP Edge® Journal Watch Issue 34 August 2026: ICD Shocks, Troponin, PFA Safety, LOSE-AF Weight Loss and POTS, Radiation Expose in the EP Lab

    What can nine carefully selected studies teach us about the changing practice of cardiac electrophysiology? In EP Edge® Journal Watch Issue 34, August 2026, Dr. Sharma provides a clinically focused review of emerging evidence across atrial fibrillation, pulsed field ablation, implantable cardiac devices, sudden death prevention, resuscitation, occupational radiation safety, and postural orthostatic tachycardia syndrome. This episode examines whether transvenous and subcutaneous ICD shocks produce different patterns of myocardial injury; the incidence and clinical meaning of migraine following pulsed field ablation; whether routine mechanical CPR improves meaningful survival after out-of-hospital cardiac arrest; and why hemolysis and renal effects may differ among PFA platforms and workflows. Dr. Sharma also explores the FINE-HEART analysis of finerenone and sudden death, the LOSE-AF randomized trial of weight loss in older patients with persistent atrial fibrillation, occupational radiation exposure during pregnancy, the prognostic significance of skin thickness over cardiac implantable electronic devices, and a randomized crossover comparison of ivabradine and propranolol for POTS. Rather than simply reciting percentages and P values, the discussion explains why each study was undertaken, how it was designed, what its principal statistical findings mean, where uncertainty remains, and how the results might—or might not—affect clinical practice. Each analysis concludes with the EP Edge take: a practical interpretation for physicians, trainees, nurses, allied professionals, and others caring for patients with heart-rhythm disorders. The episode also previews the early September 2026 arrival of EPEdge.org and the EP Edge app. Built around Knowledge · Access · Humanity, the new platform will bring together EP Edge Analytics, EP Edge Academy, CME and MOC opportunities, EP Edge Rx, practical clinical resources, and the complete EP Edge newsletter archive. And don’t miss next week’s must-listen collaborative issue with the Heart Rhythm Society. READ AND SUBSCRIBE EP Edge Journal Watch on LinkedIn:https://lnkd.in/e-Wa4diC EP Edge Newsletter on LinkedIn:https://lnkd.in/ep3NdZUz EP Edge on Substack:https://epedge.substack.com EPEdge.org—launching in early September 2026:https://epedge.org

    EP Edge® Journal Watch Issue 34 August 2026: ICD Shocks, Troponin, PFA Safety, LOSE-AF Weight Loss and POTS, Radiation Expose in the EP Lab

  3. 17. Aug.

    EP Edge® Journal Watch Issue 33, August 2026: Anticoagulation After AF Ablation, PFA Safety, Lead Extraction and Sudden Death Risk

    How long should anticoagulation continue after an apparently successful atrial fibrillation ablation? Should prophylactic pulmonary vein isolation be added during typical atrial flutter ablation in patients with heart failure? What do emerging data reveal about neurologic events, hemolysis, and renal safety with pulsed-field ablation? In EP Edge® Journal Watch Issue 33, August 2026, Dr. Sharma provides a clinically focused and thought-provoking review of nine important cardiac electrophysiology studies published in Heart Rhythm and JACC: Clinical Electrophysiology. This episode examines:  The proposed 8.1-month timing for oral anticoagulant discontinuation after successful AF ablation  Prophylactic pulmonary vein isolation in patients with typical atrial flutter and heart failure  Lesion delivery, irrigation rates, and neurovascular events with pulsed-field ablation  PFA-associated hemolysis, acute kidney injury, and platform-specific renal safety  Transvenous lead extraction outcomes in patients with prior sternotomy  First-in-human vibration-based lead extraction  The line-of-block pacing maneuver for distinguishing AV nodal from accessory pathway conduction  The SCAAF-ERS electrocardiographic score for sudden cardiac arrest risk in atrial fibrillation  A gain-of-function KCNJ8 variant linked with inherited and acquired J-wave syndromes Rather than simply listing study results, Dr. Sharma explains why each investigation was needed, what clinical uncertainty it attempted to resolve, how the methodology affects interpretation, and what the principal statistics mean in practical terms. Each paper concludes with the EP Edge Take, including the potential implications for current practice, the limitations that should temper interpretation, and the questions that future research must answer. The episode also includes updates on the EP Edge® app, the new epedge.org website, and the upcoming EP Edge® Journal Watch collaboration with the Heart Rhythm Society. Full references, study graphics, and the complete written analysis are available through the EP Edge® Journal Watch newsletter on LinkedIn and on Substack at epedge.substack.com. Questions, suggestions, or concerns can be sent to epedge.cast@gmail.com.

    EP Edge® Journal Watch Issue 33, August 2026: Anticoagulation After AF Ablation, PFA Safety, Lead Extraction and Sudden Death Risk

  4. 10. Aug.

    EP Edge® Journal Watch Issue 32 August 2026: AF Ablation Anticoagulation, Flecainide After CAST, AI-ECG & PFA Mapping

    Can anticoagulation be safely discontinued after successful atrial fibrillation ablation? Is the traditional prohibition against flecainide in structural heart disease too broad or does CAST remain an essential warning? And can AI-enabled ECGs, unipolar voltage mapping, and cardiac MRI improve how we detect AF and characterize arrhythmic substrate? In EP Edge® Journal Watch Issue 32, Dr. Niraj Sharma examines important electrophysiology research published in Heart Rhythm and JACC: Clinical Electrophysiology, translating the methodology, statistical findings, limitations, and clinical implications into practical insights for electrophysiologists and cardiovascular clinicians. Topics include: Discontinuing oral anticoagulation after AF ablationThe clinical and economic consequences of delayed AF ablationEstimating AF burden after several AF-free monitoring daysMulticenter validation of an AI-enabled ECG model for predicting AFUnipolar voltage mapping and lesion durability after pulsed field ablationHigh-density electroanatomic mapping versus cardiac MRI in nonischemic cardiomyopathyHow CAST changed the direction of flecainide researchClass Ic antiarrhythmic therapy after PCIReconsidering flecainide in selected structural heart disease phenotypesAmiodarone-associated thyrotoxicosis in patients with pre-existing hypothyroidismThe episode separates statistical association from causal evidence and asks what these findings should and should not change in current practice. It also outlines the prospective trials needed to determine whether anticoagulation withdrawal, AI-guided AF screening, voltage-guided PFA, and phenotype-based flecainide prescribing can improve clinically meaningful outcomes. Dr. Sharma also previews the next collaborative EP Edge® Journal Watch issue with the Heart Rhythm Society, the forthcoming EP Edge® app, and the new epedge.org platform—bringing podcasts, newsletters, EP Edge Rx, EP Edge Academy, and additional clinical and patient-focused resources into one accessible ecosystem. References, graphics, and the complete written analysis are available through EP Edge® Journal Watch on LinkedIn and Substack: https://epedge.substack.com Questions, suggestions, or concerns: epedge.cast@gmail.com

    EP Edge® Journal Watch Issue 32 August 2026: AF Ablation Anticoagulation, Flecainide After CAST, AI-ECG & PFA Mapping

  5. 3. Aug.

    EP Edge® Journal Watch Issue 31, August 2026: Caffeine, Wine, Atrial Fibrillation, Pulsed-Field Ablation and Sudden Cardiac Death

    In EP Edge® Journal Watch Issue 31, August 2026, Dr. Sharma examine new evidence that challenges several familiar assumptions in cardiac electrophysiology. Should patients with atrial fibrillation routinely stop drinking coffee? An American Heart Association scientific statement reviews the cardiovascular effects of caffeine, including randomized evidence showing a 39% lower risk of recurrent AF among habitual coffee drinkers who continued coffee after cardioversion. The discussion separates ordinary coffee consumption from energy drinks and concentrated caffeine while considering premature ventricular contractions, blood pressure, sleep, and individualized patient counseling. The episode also investigates whether wine adds cardiovascular benefit to the Mediterranean diet. The apparent benefit weakened when moderate drinkers were compared with very-light drinkers, demonstrating how the reference group can change the statistical narrative. Importantly, these studies did not evaluate AF outcomes and do not support prescribing wine as cardiovascular therapy. Other studies covered include: • Pulsed-field ablation for persistent AF, with pooled one-year freedom from atrial arrhythmia of 72.3%, but no proven superiority over thermal ablation. • Broad and predominantly left-sided pulmonary vein reconnection patterns during redo procedures after pentaspline pulsed-field ablation. • Real-world Sphere-9 safety reports involving ventricular arrhythmias, implanted-device interactions, stroke, AV block, and other signals, interpreted in the absence of a procedural denominator. • The SMARTBEATS randomized trial of smartphone rhythm monitoring before cardioversion, which prevented approximately one same-day cancellation for every six patients monitored. • Autopsy-based sudden cardiac death research showing that myocardial infarction accounted for 41% of confirmed sudden cardiac deaths and highlighting the limitations of ejection fraction alone. • End-tidal carbon dioxide trajectories during out-of-hospital cardiac arrest and why no single value should become a stand-alone termination rule. • Atrial fibrillation, bradycardia, conduction disease, and ventricular ectopy in masters athletes, reinforcing that exceptional fitness does not provide immunity from clinically important arrhythmias. Listen for the study rationale, methodology, clinically meaningful statistics, limitations, and the EP Edge take on how these findings may influence practice. Complete references, graphics, and detailed analysis are available through the LinkedIn newsletter EP Edge® Journal Watch and at epedge.substack.com.

    EP Edge® Journal Watch Issue 31, August 2026: Caffeine, Wine, Atrial Fibrillation, Pulsed-Field Ablation and Sudden Cardiac Death

  6. 27. Juli

    EP Edge® Journal Watch Issue 30: VISION AF, Pulsed Field Ablation Safety, PACE-HF and Conduction System Pacing | July 2026

    In EP Edge® Journal Watch Issue 30, July 2026, we explore the next phase of cardiac electrophysiology, from pulsed field ablation durability and physiologic pacing to neuromodulation, sleep, fitness, and lifetime arrhythmia risk. We begin with the first-in-human VISION AF study, which evaluates an endoscope-enabled pulsed field ablation balloon that allows direct visualization of the electrode-tissue interface. Chronic invasive remapping provides a close look at pulmonary vein isolation durability and raises an important question: could seeing tissue contact become the next major advance in PFA workflow?  Two additional studies examine practical PFA safety signals. One evaluates hemolysis-associated acute kidney injury, pulse count, chronic kidney disease, extensive left atrial ablation, and whether protocol-based hydration can reduce renal risk. Another quantifies acute blood pressure drops during circular-array PFA and identifies the first pulmonary vein treatment as the period of greatest hemodynamic vulnerability.  The pacing and ventricular arrhythmia section includes:  The randomized PACE-HF trial, comparing left bundle branch area pacing with conventional right ventricular pacing  A preclinical comparison of left bundle branch area antitachycardia pacing and right ventricular ATP  Pulsed ultrahigh-frequency spinal cord stimulation as a potential neuromodulation strategy after myocardial infarction We then move beyond the EP laboratory to examine:  Insomnia and incident atrial fibrillation  The lifetime cardiovascular tradeoff between high cardiorespiratory fitness and AF risk  Whether the balance of moderate and vigorous physical activity influences cardiovascular and overall mortality Each paper is examined through its rationale, methodology, statistical meaning, limitations, and potential clinical consequences. Can direct tissue visualization improve PFA durability? Should PFA pulse count be treated as a biologic dose? Is right ventricular pacing still acceptable when substantial pacing is anticipated? Could the site of antitachycardia pacing determine whether VT terminates? How should clinicians incorporate sleep and exercise into arrhythmia prevention? This episode is intended for electrophysiologists, cardiologists, device specialists, fellows, researchers, and anyone following advances in pulsed field ablation, conduction system pacing, ventricular arrhythmia therapy, and preventive cardiology. Read the companion newsletter and subscribe to EP Edge® Journal Watch at epedge.substack.com.

    EP Edge® Journal Watch Issue 30: VISION AF, Pulsed Field Ablation Safety, PACE-HF and Conduction System Pacing | July 2026

  7. 20. Juli

    EP Edge® Journal Watch Issue 29: Atrial Fibrillation Ablation vs Antiarrhythmic Drugs, CABANA Progression and Anticoagulation | July 2026

    In EP Edge® Journal Watch Issue 29, July 2026, we examine the evidence reshaping contemporary atrial fibrillation management and the rapidly changing role of catheter ablation. Two major meta-analyses compare catheter ablation with antiarrhythmic drug therapy, addressing rhythm efficacy, serious adverse events, hospitalization, treatment intolerance, and whether medications still deserve an automatic safety advantage. We also review real-world outcomes in older adults after prior antiarrhythmic drug exposure and ask whether another medication or catheter ablation is the more appropriate next step.  The episode then explores whether ablation can modify the natural history of AF. A CABANA analysis evaluates progression from paroxysmal to persistent AF, while new registry data challenge the assumption that asymptomatic AF represents a low-risk phenotype. The SUPPRESS-AF analysis examines whether low-voltage area ablation should be guided by the amount of abnormal atrial substrate rather than applied uniformly.  We also discuss:  Urgent versus elective inpatient AF ablation  Oral anticoagulation after apparently successful AF ablation  The age-dependent relationship between heart failure and ischemic stroke  The SLASH score for predicting AF recurrence after electrical cardioversion Each study is reviewed through its clinical rationale, methodology, statistical interpretation, limitations, and practical implications for electrophysiology practice. Should catheter ablation move earlier in the AF treatment pathway? Should symptom status continue to determine access to rhythm control? When is urgent inpatient ablation justified? Does successful ablation ever eliminate the need for anticoagulation? This episode is designed for cardiac electrophysiologists, cardiologists, fellows, researchers, and clinicians seeking a detailed, clinically relevant review of the latest atrial fibrillation evidence. Read the companion newsletter and subscribe to EP Edge® Journal Watch at epedge.substack.com.

    EP Edge® Journal Watch Issue 29: Atrial Fibrillation Ablation vs Antiarrhythmic Drugs, CABANA Progression and Anticoagulation | July 2026

  8. 13. Juli

    EP Edge × HRS Podcast: CT-Guided VT Ablation & LAA Closure Without AF: InEurHeart and OPINION, Caveolae, Alcohol and AFib, Pulse check and Afib Diagnosis

    In this July 2026 episode of EP Edge Journal Watch, produced in collaboration with the Heart Rhythm Society (HRS), Mike Lloyd and Dr. Niraj Sharma review five studies with direct implications for contemporary cardiac electrophysiology practice. The anchor trials are InEurHeart, a randomized comparison of computed tomography-guided versus conventional catheter ablation for post–myocardial infarction ventricular tachycardia, and OPINION, which evaluates prophylactic surgical left atrial appendage occlusion during valvular heart surgery in patients without known pre-existing atrial fibrillation. Using the workflow gains seen with pulsed field ablation in AF as context, the discussion asks whether preprocedural cardiac CT can make ischemic VT ablation more efficient while preserving the essential role of functional mapping and why future AF risk should not automatically lead to surgical LAA closure. Rapid-fire analyses cover the relationship between alcohol consumption and incident atrial fibrillation, pulse self-examination as a simple strategy to improve AF detection, and emerging mechanistic research on caveolae, pacemaker signaling, sinus node dysfunction, and heart failure. The episode translates randomized trials, meta-analysis, screening research, and translational science into practical implications for the EP lab, clinic, patient counseling, and shared decision-making. Essential listening for electrophysiologists, cardiologists, fellows, advanced practice clinicians, and cardiac rhythm-management teams

    EP Edge × HRS Podcast: CT-Guided VT Ablation & LAA Closure Without AF: InEurHeart and OPINION, Caveolae, Alcohol and AFib, Pulse check and Afib Diagnosis
Alle anzeigen (43)

Info

Welcome to EP Edge Journal Watch, where cardiac electrophysiology meets evidence, precision, and perspective. Hosted by Dr. Niraj Sharma, this weekly podcast distills high-impact cardiovascular and Cardiac Electrophysiology and arrhythmia research into clear, clinically meaningful insights. Each episode goes beyond headlines and abstracts to uncover what new studies actually mean for patient care, decision-making, and the future of electrophysiology. What EP Edge Journal Watch stands for: Evidence-based practice Precision electrophysiology, arrhythmias analysis A forward-thinking, edge-driven approach to how we interpret and apply data in real-world clinical settings. Whether you’re an electrophysiologist, cardiologist, researcher, trainee, or allied health professional, EP Edge Journal Watch brings you the signal not the noise. Expect sharp summaries, thoughtful commentary, and practical takeaways designed for the busy clinician who wants to stay ahead of the curve

Informationen

  • Erstellt von
    Niraj Sharma MD FACC FHRS: Cardiac Electrophysiology & Cardiology
  • Jahre aktiv
    2025 - 2026
  • Folgen
    43
  • Bewertung
    Unbedenklich
  • Copyright
    © 2026 Niraj Sharma MD FACC FHRS: Cardiac Electrophysiology & Cardiology
  • Anbieter